WTX101 – an investigational drug for the treatment of Wilson disease

References

• Ferenci P. Regional distribution of mutations of the ATP7B gene in patients with Wilson disease: impact on genetic testing. Hum Genet. 2006;120:151–159.
   PubMed Web of Science ®Google Scholar
• Hedera P. Update on the clinical management of Wilson’s disease. Appl Clin Genet. 2017;10:9–19.
   PubMedGoogle Scholar
• Weiss KH, Stremmel W. Clinical considerations for an effective medical therapy in Wilson’s disease. Ann N Y Acad Sci. 2014;1315:81–85.
   PubMed Web of Science ®Google Scholar
• Roberts EA, Schilsky ML. American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. Hepatology. 2008;47:2089–2111.
   PubMed Web of Science ®Google Scholar
• Coffey AJ, Durkie M, Hague S, et al. A genetic study of Wilson’s disease in the United Kingdom. Brain. 2013;136:1476–1487.
   PubMed Web of Science ®Google Scholar
• Bandmann O, Weiss KH, Kaler SG. Wilson’s disease and other neurological copper disorders. Lancet Neurol. 2015;14:103–113.
   PubMed Web of Science ®Google Scholar
• Jang JH, Lee T, Bang S, et al. Carrier frequency of Wilson’s disease in the Korean population: a DNA-based approach. J Hum Genet. 2017;62:815–818.
   PubMed Web of Science ®Google Scholar
• Steindl P, Ferenci P, Dienes HP, et al. Wilson’s disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology. 1997;113:212–218.
   PubMed Web of Science ®Google Scholar
• European association for study of liver. EASL clinical practice guidelines: Wilson’s disease. J Hepatol. 2012;56:671–685.
   PubMed Web of Science ®Google Scholar
• Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int. 2003;23:139–142.
   PubMed Web of Science ®Google Scholar
• Beinhardt S, Leiss W, Stättermayer AF, et al. Long-term outcomes of patients with Wilson disease in a large Austrian cohort. Clin Gastroenterol Hepatol. 2014;12:683–689.
   PubMed Web of Science ®Google Scholar
• Merle U, Schaefer M, Ferenci P, et al. Clinical presentation, diagnosis and long-term outcome of Wilson’s disease: a cohort study. Gut. 2007;56:115–120.
   PubMed Web of Science ®Google Scholar
• Członkowska A, Litwin T, Karliński M, et al. D-Penicillamine versus zinc sulfate as first-line therapy for Wilson’s disease. Eur J Neurol. 2014;21:599–606.
   PubMed Web of Science ®Google Scholar
• Weiss KH, Thurik F, Gotthardt DN, et al. Efficacy and safety of oral chelators in treatment of patients with Wilson disease. Clin Gastroenterol Hepatol. 2013;11:1028–1035.
   PubMed Web of Science ®Google Scholar
• Brewer GJ, Askari F, Lorincz MT, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol. 2006;63:521–527.
   PubMed Web of Science ®Google Scholar
• Litwin T, Dzieżyc K, Karliński M, et al. Early neurological worsening in patients with Wilson’s disease. J Neurol Sci. 2015;355:162–167.
   PubMed Web of Science ®Google Scholar
• Wiernicka A, Jańczyk W, Dądalski M, et al. Gastrointestinal side effects in children with Wilson’s disease treated with zinc sulphate. World J Gastroenterol. 2013;19:4356–4362.
   PubMed Web of Science ®Google Scholar
• Weiss KH, Gotthardt DN, Klemm D, et al. Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease. Gastroenterology. 2011;140:1189–1198.
   PubMed Web of Science ®Google Scholar
• Masełbas W, Chabik G, Członkowska A. Persistence with treatment in patients with Wilson disease. Neurol Neurochir Pol. 2010;44:260–263.
   PubMed Web of Science ®Google Scholar
• Dzieżyc K, Karliński M, Litwin T, et al. Compliant treatment with anti-copper agents prevents clinically overt Wilson’s disease in pre-symptomatic patients. Eur J Neurol. 2014;21:332–337.
   PubMed Web of Science ®Google Scholar
• Brewer GJ, Askari F, Dick RB, et al. Treatment of Wilson’s disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine. Transl Res. 2009;154:70–77.
   PubMed Web of Science ®Google Scholar
• Brewer GJ. The use of copper-lowering therapy with tetrathiomolybdate in medicine. Expert Opin Investig Drugs. 2009;18:89–97.
   PubMed Web of Science ®Google Scholar
• Grimm G, Oder W, Prayer L, et al. Evoked potentials in assessment and follow-up of patients with Wilson’s disease. Lancet. 1990;336:963–964.
   PubMed Web of Science ®Google Scholar
• Schilsky ML, Scheinberg IH, Sternlieb I. Prognosis of Wilsonian chronic active hepatitis. Gastroenterology. 1991;100:762–767.
   PubMed Web of Science ®Google Scholar
• Houwen R. Bis-choline tetrathiomolybdate for Wilson’s disease. Lancet Gastroenterol Hepatol. 2017;2:839–840.
   PubMed Web of Science ®Google Scholar
• Scheinberg IH, Jaffe ME, Sternlieb I. The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson’s disease. N Engl J Med. 1987;317:209–213.
   PubMed Web of Science ®Google Scholar
• Medici V, Trevisan CP, D’Incà R, et al. Diagnosis and management of Wilson’s disease: results of a single center experience. J Clin Gastroenterol. 2006;40:936–941.
   PubMed Web of Science ®Google Scholar
• Cope-Yokoyama S, Finegold MJ, Sturniolo GC, et al. Wilson disease: histopathological correlations with treatment on follow-up liver biopsies. World J Gastroenterol. 2010;16:1487–1494.
   PubMed Web of Science ®Google Scholar
• Brewer GJ, Hill GM, Dick RD, et al. Treatment of Wilson’s disease with zinc: III. Prevention of reaccumulation of hepatic copper. J Lab Clin Med. 1987;109:526–531.
   PubMed Web of Science ®Google Scholar
• Mason J, McQuaid A, Pheiffer H. Can Wilson’s disease patients be decoppered? Lancet. 1989;1:1455.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Vist GE, et al. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–926.
   PubMed Web of Science ®Google Scholar
• Ogra Y, Suzuki KT. Removal and efflux of copper from Cu-metallothionein as Cu/tetrathiomolybdate complex in LEC rats. Res Commun Mol Pathol Pharmacol. 1995;88:196–204.
   PubMedGoogle Scholar
• Brewer GJ, Dick RD, Yuzbasiyan-Gurkin V, et al. Initial therapy of patients with Wilson’s disease with tetrathiomolybdate. Arch Neurol. 1991;48:42–47.
   PubMed Web of Science ®Google Scholar
• Brewer GJ, Dick RD, Johnson V, et al. Treatment of Wilson’s disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients. Arch Neurol. 1994;51:545–554.
   PubMed Web of Science ®Google Scholar
• Brewer GJ, Johnson V, Dick RD, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch Neurol. 1996;53:1017–1025.
   PubMed Web of Science ®Google Scholar
• Brewer GJ, Hedera P, Kluin KJ, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol. 2003;60:379–385.
   PubMed Web of Science ®Google Scholar
• Lin J, Zahurak M, Beer TM, et al. A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer. Urol Oncol. 2013;31:581–588.
   PubMed Web of Science ®Google Scholar
• Lowndes SA, Adams A, Timms A, et al. Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors. Clin Cancer Res. 2008;14:7526–7534.
   PubMed Web of Science ®Google Scholar
• Askari F, Innis D, Dick RB, et al. Treatment of primary biliary cirrhosis with tetrathiomolybdate: results of a double-blind trial. Transl Res. 2010;155:123–130.
   PubMed Web of Science ®Google Scholar
• Chan N, Willis A, Kornhauser N, et al. Influencing the tumor microenvironment: A phase II study of copper depletion using tetrathiomolybdate in patients with breast cancer at high risk for recurrence and in preclinical models of lung metastases. Clin Cancer Res. 2017;23:666–676.
   PubMed Web of Science ®Google Scholar
• Jain S, Cohen J, Ward MM, et al. Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse. Ann Oncol. 2013;24:1491–1498.
   PubMed Web of Science ®Google Scholar
• Ogra Y, Ohmichi M, Suzuki KT. Mechanisms of selective copper removal by tetrathiomolybdate from metallothionein in LEC rats. Toxicology. 1996;106:75–83.
   PubMed Web of Science ®Google Scholar
• Suzuki KT. Disordered copper metabolism in LEC rats, an animal model of Wilson disease: roles of metallothionein. Res Comm Mol Pathol Pharmacol. 1995;89:221–240.
   PubMedGoogle Scholar
• Komatsu Y, Sadakata I, Ogra Y, et al. Excretion of copper complexed with thiomolybdate into the bile and blood in LEC rats. Chem Biol Interact. 2000;124:217–231.
   PubMed Web of Science ®Google Scholar
• Říha M, Karlíčková J, Filipský T, et al. Novel method for rapid copper chelation assessment confirmed low affinity of D-penicillamine for copper in comparison with trientine and 8-hydroxyquinolines. J Inorg Biochem. 2013;123:80–87.
   PubMed Web of Science ®Google Scholar
• Zhang JW, Liu JX, Hou HM, et al. Effects of tetrathiomolybdate and penicillamine on brain hydroxyl radical and free copper levels: a microdialysis study in vivo. Biochem Biophys Res Commun. 2015;458:82–85.
   PubMed Web of Science ®Google Scholar
• Smirnova J, Kabin E, Jarving I, et al. Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α-Lipoic acid as a potential anti-copper agent. Sci Rep. 2018;8:1463.
   PubMed Web of Science ®Google Scholar
• Plitz T, Boyling L. Metabolic disposition of WTX101 (bis-choline tetrathiomolybdate) in a rat model of Wilson disease. Xenobiotica. 2018 Feb 27;1–7. Epub ahead of print. DOI:10.1080/00498254.2018.1443352
   PubMedGoogle Scholar
• Weiss KH, Askari FK, Czlonkowska A, et al. Bis-choline tetrathiomolybdate in patients with Wilson’s disease: an open-label, multicentre, phase 2 study. Lancet Gastroenterol Hepatol. 2017;2:869–876.
   PubMed Web of Science ®Google Scholar
• Członkowska A, Tarnacka B, Möller JC, et al. Unified Wilson’s Disease Rating Scale – a proposal for the neurological scoring of Wilson’s disease patients. Neurol Neurochir Pol. 2007;41:1–12.
   PubMed Web of Science ®Google Scholar
• Dhawan A, Taylor RM, Cheeseman P, et al. Wilson’s disease in children: 37-year experience and revised King’s score for liver transplantation. Liver Transpl. 2005;11:441–448.
   PubMed Web of Science ®Google Scholar
• Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–470.
   PubMed Web of Science ®Google Scholar
• Weiss KH, Askari FK, Ferenci P, et al. Long-term efficacy and safety of WTX101 in Wilson disease: data from an ongoing extension of a phase 2 study (WTX101-201). J Hepatol. 2018;68(Suppl 1):S105.
   Google Scholar